ETEST FOR GEMIFLOXACIN

K042390 · Ab Biodisk · JWY · Nov 19, 2004 · Microbiology

Device Facts

• Record ID: K042390
• Device Name: ETEST FOR GEMIFLOXACIN
• Applicant: Ab Biodisk
• Product Code: JWY · Microbiology
• Decision Date: Nov 19, 2004
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.1640
• Device Class: Class 2

Intended Use

Etest® is a quantitative technique for determining the antimicrobial susceptibility testing of both non-fastidious Gram-negative and Gram positive aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species and fastidious bacteria, such as anaerobes N. gonorrhoeae, S. pneumoniae, Streptococcus and Haemophilus species. It uses a predefined antibiotic gradient to determine the Minimum Inhibitory Concentration (MIC) in µg/mL of different antimicrobial agents against microorganisms as tested on agar media using overnight incubation.

Device Story

Etest® is a manual antimicrobial susceptibility test (AST) system. It consists of a 5mm x 60mm inert plastic strip containing a predefined exponential gradient of dried, stabilized antibiotic. The strip is applied to an inoculated agar plate; the antibiotic diffuses into the agar, creating a concentration gradient. After overnight incubation, a symmetrical inhibition ellipse forms around the strip. The clinician reads the Minimum Inhibitory Concentration (MIC) at the point where the ellipse edge intersects the strip. The device provides quantitative MIC values, which are used by healthcare providers to determine bacterial susceptibility to gemifloxacin, aiding in the selection of appropriate antimicrobial therapy. It is intended for use in clinical laboratory settings.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on bench testing performance characteristics for the determination of MIC values for Gemifloxacin against specified bacterial isolates.

Technological Characteristics

Quantitative antimicrobial susceptibility test strip; predefined antibiotic gradient; manual application to agar media; overnight incubation; visual MIC determination via growth inhibition ellipse intersection.

Indications for Use

Indicated for testing Enterobacteriaceae, S. pneumoniae, and H. influenzae for susceptibility to gemifloxacin (0.002 – 32 µg/mL). For prescription use.

Regulatory Classification

Identification

An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle or bird-like symbol with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

NOV 1 9 2004

Ms. Anne Bolmström President & CEO AB Biodisk Dalvägen 10 S-169 56 Solna Sweden

k042390 Re: Trade/Device Name: Etest® Gemifloxacin 0.002-32 µg/mL Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial Susceptibility Test Powder Regulatory Class: Class II Product Code: JWY Dated: November 10, 2004 Received: November 12, 2004

Dear Ms. Bolmström:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{1}------------------------------------------------

## Page 2

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Salartys

Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known): k042390

Device Name: Etest® Gemifloxacin 0.002-32 µg/mL

Indications For Use:

For in vitro diagnostic use:

Etest is a quantitative technique for the determination of antimicrobial susceptibility of both nonfastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaxeae, Pseudomonas, Staphylooocus and Enteroous species and fastidious bacteria, such as anaerobes, Pneumooocus, Streptocous, Gonocous and Haemophilus species. The system comprises a predefined antibiotic gradient that is used to determine the minimum inhibitory concentration (MIC) in µg/ml of individual antibiotics against bacteria as tested on agar media by overnight incubation.

This 510(k) submission is for an additional drug for Etest for MIC determination of Gemifloxacin MIC 0.002 - 32 µg/ml with Enterobacteriaceae, S. pneumoniae and H. influenzae.

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Ludolfo-Rocle

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K^{04}23^{D} Si

Page 1 of _1

C:\Documents and Settings\MBB\Desktop\O\VD\Review AST 510K\AB Biodisk\k042390 gemifloxacin\IFU 0410-1.00C